Meclizine for Hepatocellular Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 13, 2017

Primary Completion Date

March 28, 2023

Study Completion Date

March 28, 2023

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Meclizine Oral Tablet

All subjects will receive 50 mg of meclizine taken orally, twice a day (daily dose 100 mg) for 28 (up to 35) days.

Trial Locations (5)

77030

Baylor College of Medicine -McNair Campus, Houston

Baylor College of Medicine, Houston

Baylor St. Luke's Medical Center, Houston

Ben Taub General Hospital, Houston

Harris Health System- Smith Clinic, Houston

All Listed Sponsors
lead

Tannaz Armaghnay

OTHER

NCT03253289 - Meclizine for Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter